CAS: 13209-41-1; (8S,10S,13S,14S,16R,17R)-17-Hydroxy-17-(2-Hydroxyacetyl)-10,13,16-Trimethyl-6,7,8,10,12,13,14,15,16,17-Decahydro-3H-Cyclopenta[a]Phenanthren-3-One (Dexamethasone Impurity)
该化合物是一种合成类类固醇,属于气候类固醇,其特点是一种复杂的类固醇结构,由多种氢氧基(-OH)组组成,有助于其生物活动,16-甲基组和类核中特定的双联影响其药性,包括防炎和免疫抑制作用,这种化合物经常被研究其潜在的治疗用途,特别是在治疗与免疫系统有关的各种炎症和疾病方面,其溶解性,稳定性和与生物受体的相互作用是决定其功效和安全状况的关键因素.与许多类固醇一样,它可能呈现一系列副作用,需要在临床使用中仔细考虑.
- 英文名称(8S,10S,13S,14S,16R,17R)-17-Hydroxy-17-(2-Hydroxyacetyl)-10,13,16-Trimethyl-6,7,8,10,12,13,14,15,16,17-Decahydro-3H-Cyclopenta[a]Phenanthren-3-One (Dexamethasone Impurity)
- 中文名称(8S,10S,13S,14S,16R,17R)-17-羟基-17-(2-羟基乙酰基)-10,13,16-三甲基-6,7,8,10,12,13,14,15,16,17-十氢-3H-环戊并[a]菲-3-酮(地塞米松杂质)
- IUPAC名称(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one
- 其它别名Pregna-1,4,9(11)-triene-3,20-dione,17,21-dihydroxy-16a-methyl- (6CI,7CI,8CI); 17a,21-Dihydroxy-16a-methylpregna-1,4,9(11)-triene-3,20-dione
- CAS编号13209-41-1
- MFCD编号:MFCD18452727
- EINECS号:236-177-8
- FDA UNII编号:8XP29XMB43
- 分子式:C22H28O4分子量:356.46
- 产品CID: 487216
- 同类组份化合物CAS10106-41-9 (acetate)13209-41-1 (free base)
- 产品分类有机原料→分析科学→药物杂质对照品→其他类→其他杂质
相似化合物
13504-15-9 910-99-6 96002-49-2物理性质
- 熔点228-231°C
- 沸点548.3±50.0 °C(预测)
- 闪点299.4 °C
- 密度1.24±0.1 g/cm3(预测)
- pKa:12.53±0.70(预测)
- PSA:74.6
- LogP:2.7529
- 蒸汽压2.63E-14 mmHg at 25 °C
- 溶解性Chloroform (Slightly), Dioxane (Slightly), Ethyl Acetate (Slightly)
- 外观形态淡黄色固体
- 储存条件冰箱
- 产品应用该化合物是一流的分解性抗食炎抗炎药物,在体外和活体生物活性中表现出强力,比传统甘蓝类动物安全性比强.在体内,VAMOLOLONE有选择地结合了凝球受体(GR)并有效抑制了NF-XXB等阻燃性信号途径,导致细胞细胞反应减少,包括TNF-Α,IL-1Β和IL-6,同时尽量减少与副作用有关的转活性相关基因表达.在细胞分析中,它保留了与前鼻血球相似的抗食性药,但显示出细胞毒性和氧化性压力降低.在活性反应中,VOMOLONE在DUCHEN 肌肉萎缩性动物模型中显示出显著的功效,在这种模型中,它可以改善肌肉强度,减少纤维分裂性,减少炎性渗透性渗透.
MSDS等安全信息
欧盟法规
ECHA物质C&L通报REACH预注册上下游产品
2-((10S,13S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-°Ctahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 2-((10S,13S,16R,17R)-17-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-°Ctahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate dexamethasone合成工艺路线路线简述
📜在 盐酸体系中,用 戊醇 用作溶剂,以80%的收率获得17,21-二羟基-16Alpha-甲基孕甾-1,4,9(11)-三烯-3,20-二酮
参考文献:一种17,21-双羟基甾体衍生物的制备方法
标题:一种17,21-双羟基甾体衍生物的制备方法
摘要:本发明涉及一种以甾体烯醇硅醚化合物i为起始物制备17,21‑双羟基甾体化合物iii的方法.
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905143000-叔丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2023016817-A1
优先权日:2021-08-12
标 题:Synthesis of delta 9,11 steroids
专利号:EP-4384529-A1
优先权日:2021-08-12
标题:Synthesis of delta 9,11 steroids
专利号:CN-117858886-A
优先权日:2021-08-12
标题 :Synthesis of Δ9,11-steroids
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Murphy C, Nasomyont N, Tian C, Ryan TD, Villa C, Reebals L, Zygmunt A, Rutter MM. From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinicians. Neuromuscul Disord. 2026 Mar 14;62:106411. doi: 10.1016/j.nmd.2026.106411. Epub ahead of print. 273(3):177. doi: 10.1007/s00415-026-13711-6.
3: Sbrocchi AM, Kinnett K, Lautatzis ME, McMillan HJ, Selby KA, Veerapandiyan A, Weber DR, Apkon S, Bharucha-Goebel DX, Bharill S, Bansal S, Clemens PR, Fiscaletti M, Halloun R, Lam C, Merchant N, McAdam L, Nasomyont N, Nicolau S, Ochoa Molina MF, Phung K, Rutter MM, Scavina M, Surampudi PN, Tamaroff J, Tian C, Ward LM, Wood CL, Wong SC, Ahmet A; OPTIMIZE DMD Consortium. Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone. J Endocr Soc. 2025 Nov 27;10(2):bvaf181. doi: 10.1210/jendso/bvaf181.
4: Jazbinšek S, Vrščaj E, Šuput Omladič J, Butenko T, Loboda T, Kotnik P, Osredkar D. Endocrine and metabolic complications in a national cohort of Slovene children and adolescents with Duchenne muscular dystrophy: real-world criteria for transition to vamorolone therapy. Front Endocrinol (Lausanne). 2025 Dec 5;16:1697907. doi: 10.3389/fendo.2025.1697907.
合成参考文献
摘要:Kleemann A., Kutscher B., Reichert D., Bossart M., Pharmaceutical Substances, Thieme [Online], Stuttgart, (2025).
📝 需求与反馈
尽可能描述清楚需求与问题信息
